SCHEMBL19080162

SCHEMBL19080162

c1cc(-c2ccc3ccc4c(oc5ccc6ccccc6c54)c3c2)cc(-c2c3ccccc3c(-c3ccc4oc5ccccc5c4c3)c3ccccc23)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 3/20 0.39
PLA2G4A P47712 3/20 0.39
PLA2G10 O15496 1/20 0.39
TDP1 Q9NUW8 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ABCG2 Q9UNQ0 6/20 0.39
CYP1A1 P04798 4/20 0.39
CYP1A2 P05177 3/20 0.39
AHR P35869 2/20 0.39
PAX8 Q06710 2/20 0.39
FYN P06241 1/20 0.39
MAPK3 P27361 1/20 0.39
KDM4E B2RXH2 3/20 0.36
MAPT P10636 3/20 0.36
HPGD P15428 3/20 0.36
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17122709 0.91 PLA2G2A (0.41) PLA2G2APLA2G4APLA2G10TDP1ABCG2
SCHEMBL19079937 0.91 CYP1A1 (0.44) PLA2G2APLA2G4APLA2G10TDP1ABCG2
SCHEMBL20127318 0.91 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10TDP1L3MBTL1
SCHEMBL20127591 0.90 TDP1 (0.43) PLA2G2APLA2G4APLA2G10TDP1L3MBTL1
SCHEMBL19080003 0.90 CYP1A1 (0.44) TDP1ABCG2CYP1A1CYP1A2AHR
SCHEMBL24469229 0.90 ALOX5 (0.41) PLA2G2APLA2G4APLA2G10TDP1L3MBTL1
SCHEMBL22546776 0.90 ALOX5 (0.38) PLA2G2APLA2G4APLA2G10TDP1L3MBTL1
SCHEMBL20127539 0.89 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10ABCG2CYP1A1
SCHEMBL23060307 0.89 CYP1A1 (0.40) PLA2G2APLA2G4APLA2G10TDP1ABCG2
SCHEMBL12338264 0.89 TDP1 (0.41) PLA2G2APLA2G4APLA2G10TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10580999-B2 Condensed cyclic compound and an organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2020-03-03 US disclosed
US-20170194571-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-07-06 US disclosed
US-20170194571-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170194571-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNA1 PLA2G2A 4537/4885PLA2G4A 4462/4885PLA2G10 4289/4885
US-10580999-B2 Condensed cyclic compound and an organic light-emitting device including the same CRY1, CRY2, CCNA1 PLA2G2A 4537/4885PLA2G4A 4462/4885PLA2G10 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.